Allergan, Inc. v. Sandoz Inc., No. 14-1275 (Fed. Cir. Aug. 4, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Sandoz Inc. (“Sandoz”), Lupin Ltd. and Lupin Pha r- maceuticals, Inc. ( collectively, “Lupin”), and Hi -Tech Pharmacal Co., Inc. (“Hi-Tech”) (collectively, “the Appe l- lants”)1 appeal from the decision of the United States District Court for the Eastern District of Texas , following a bench trial, which held that the claims of U.S. Patents 7,851,504 ( the “ ’504 patent”), 8,278,353 ( the “ ’353 p a- tent”), 8,299,118 (the “ ’118 patent”), 8,309,605 ( the “ ’605 patent”), and 8,338,479 ( the “ ’479 patent”) , asserted by Allergan, Inc.